PD-L2 may possibly exert some influence over the developing tumor microenvironment by a different mechanism than PD-1–PD-L1 binding, therefore PD-L2 might be a promising newer target for antitumor immunotherapy. This evidence concerns the gene PDCD1LG2 and neoplasm.